Plasma Lipidomic Profiles of Kidney, Breast, and Prostate Cancer Patients Differ from Healthy Controls

Abstract Early cancer screening is one of the unmet needs in clinical medicine. The peripheral blood analysis is a preferred method for efficient population screening as blood collection is well embedded in clinical practice and minimally invasive for patients. Lipids are important biomolecules, and variations in lipid concentrations may reflect pathological disorders. The lipidomic profiling by ultrahigh-performance supercritical fluid chromatography hyphenated to mass spectrometry of human plasma for distinguishing samples obtained from breast, kidney, and prostate cancer patients and healthy controls is investigated. The mean sensitivity, specificity, and accuracy of the new lipidomic profiling approach were 85%, 95%, and 92% for kidney cancer; 91%, 97%, and 94% for breast cancer; and 87%, 95%, and 92% for prostate cancer. No association of statistical models with tumor stage is observed. The statistically most significant lipid species for differentiation of studied cancer types are CE 16:0, Cer 42:1, LPC 18:2, PC 36:2, PC 36:3, SM 32:1, and SM 41:1.

Download Full-text

Plasma lipidomic profiles of kidney, breast and prostate cancer patients differ from healthy controls

Scientific Reports ◽

10.1038/s41598-021-99586-1 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Denise Wolrab ◽

Robert Jirásko ◽

Ondřej Peterka ◽

Jakub Idkowiak ◽

Michaela Chocholoušková ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Medicine ◽

Prostate Cancer Screening ◽

Blood Analysis ◽

Blood Collection ◽

Healthy Controls ◽

Lipid Profiling ◽

Potential Biomarker ◽

Lipid Species ◽

Breast And Prostate Cancer

AbstractEarly detection of cancer is one of the unmet needs in clinical medicine. Peripheral blood analysis is a preferred method for efficient population screening, because blood collection is well embedded in clinical practice and minimally invasive for patients. Lipids are important biomolecules, and variations in lipid concentrations can reflect pathological disorders. Lipidomic profiling of human plasma by the coupling of ultrahigh-performance supercritical fluid chromatography and mass spectrometry is investigated with the aim to distinguish patients with breast, kidney, and prostate cancers from healthy controls. The mean sensitivity, specificity, and accuracy of the lipid profiling approach were 85%, 95%, and 92% for kidney cancer; 91%, 97%, and 94% for breast cancer; and 87%, 95%, and 92% for prostate cancer. No association of statistical models with tumor stage is observed. The statistically most significant lipid species for the differentiation of cancer types studied are CE 16:0, Cer 42:1, LPC 18:2, PC 36:2, PC 36:3, SM 32:1, and SM 41:1 These seven lipids represent a potential biomarker panel for kidney, breast, and prostate cancer screening, but a further verification step in a prospective study has to be performed to verify clinical utility.

Download Full-text

Hemochromatosis gene mutations among Finnish male breast and prostate cancer patients

International Journal of Cancer ◽

10.1002/ijc.21331 ◽

2006 ◽

Vol 118 (2) ◽

pp. 518-520 ◽

Cited By ~ 16

Author(s):

Kirsi Syrjäkoski ◽

Henna Fredriksson ◽

Tarja Ikonen ◽

Tuula Kuukasjärvi ◽

Ville Autio ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Gene Mutations ◽

Male Breast ◽

Hemochromatosis Gene ◽

Breast And Prostate Cancer

Download Full-text

Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker

BMC Cancer ◽

10.1186/s12885-015-1073-8 ◽

2015 ◽

Vol 15 (1) ◽

Cited By ~ 17

Author(s):

Kiran Kumar Jagarlamudi ◽

Lars Olof Hansson ◽

Staffan Eriksson

Keyword(s):

Prostate Cancer ◽

Thymidine Kinase ◽

Cancer Patients ◽

Blood Donors ◽

Hematological Malignancies ◽

Thymidine Kinase 1 ◽

Specific Activities ◽

Breast And Prostate Cancer ◽

Serum Thymidine Kinase 1

Download Full-text

P048 Correlation between the levels of metastases-related serum markers and the presence of circulating tumor cells in breast and prostate cancer patients

European Urology Supplements ◽

10.1016/s1569-9056(14)61271-9 ◽

2014 ◽

Vol 13 (5) ◽

pp. 126-127

Author(s):

M. lančíková ◽

V. Mikulová ◽

O. Čapoun ◽

V. Soukup ◽

P. Tesarova ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Serum Markers ◽

Breast And Prostate Cancer

Download Full-text

Added value of radiological tumor stage in predicting early oncological outcomes in prostate cancer patients undergoing radical prostatectomy within clinical stage: A stage-by-stage analysis

European Urology ◽

10.1016/s0302-2838(21)01292-6 ◽

2021 ◽

Vol 79 ◽

pp. S1287-S1288

Author(s):

G. Gandaglia ◽

E. Mazzone ◽

F. Barletta ◽

G. Cirulli ◽

S. Scuderi ◽

...

Keyword(s):

Prostate Cancer ◽

Radical Prostatectomy ◽

Cancer Patients ◽

Clinical Stage ◽

Tumor Stage ◽

Added Value ◽

Oncological Outcomes ◽

Stage Analysis

Download Full-text

Abstract 681: Prospective study for the identification of DNA repair radiotoxicity biomarkers in breast and prostate cancer patients: Cohort description and descriptive statistics

10.1158/1538-7445.am2021-681 ◽

2021 ◽

Author(s):

Sylvie Sauvaigo ◽

Giovanna Muggiolu ◽

Sarah Libert ◽

Elisabeth Daguenet ◽

Claire Rodriguez-Lafrasse ◽

...

Keyword(s):

Prostate Cancer ◽

Dna Repair ◽

Prospective Study ◽

Cancer Patients ◽

Descriptive Statistics ◽

Breast And Prostate Cancer

Download Full-text

Carbonic Anhydrase I as a New Plasma Biomarker for Prostate Cancer

ISRN Oncology ◽

10.5402/2012/768190 ◽

2012 ◽

Vol 2012 ◽

pp. 1-10 ◽

Cited By ~ 5

Author(s):

Michiko Takakura ◽

Akira Yokomizo ◽

Yoshinori Tanaka ◽

Michimoto Kobayashi ◽

Giman Jung ◽

...

Keyword(s):

Prostate Cancer ◽

Carbonic Anhydrase ◽

Cancer Patients ◽

Plasma Proteins ◽

Specific Antigen ◽

Healthy Controls ◽

Gray Zone ◽

Plasma Biomarker ◽

Carbonic Anhydrase I ◽

Discrimination Rate

Serum prostate-specific antigen (PSA) levels ranging from 4 to 10 ng/mL is considered a diagnostic gray zone for detecting prostate cancer because biopsies reveal no evidence of cancer in 75% of these subjects. Our goal was to discover a new highly specific biomarker for prostate cancer by analyzing plasma proteins using a proteomic technique. Enriched plasma proteins from 25 prostate cancer patients and 15 healthy controls were analyzed using a label-free quantitative shotgun proteomics platform called 2DICAL (2-dimensional image converted analysis of liquid chromatography and mass spectrometry) and candidate biomarkers were searched. Among the 40,678 identified mass spectrum (MS) peaks, 117 peaks significantly differed between prostate cancer patients and healthy controls. Ten peaks matched carbonic anhydrase I (CAI) by tandem MS. Independent immunological assays revealed that plasma CAI levels in 54 prostate cancer patients were significantly higher than those in 60 healthy controls (, Mann-Whitney test). In the PSA gray-zone group, the discrimination rate of prostate cancer patients increased by considering plasma CAI levels. CAI can potentially serve as a valuable plasma biomarker and the combination of PSA and CAI may have great advantages for diagnosing prostate cancer in patients with gray-zone PSA level.

Download Full-text